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Vigabatrin (VGB) is a novel antiepileptic drug effective as adjunctive therapy in patients with partial seizures. In this study, the
efficacy and tolerability of VGB as adjunctive therapy were evaluated in patients with refractory epilepsy.
Adult patients with a definite diagnosis of complex partial seizures and/or partial seizures secondarily generalized were
recruited from 10 Canadian centres. Patients were randomized to receive either active medication or placebo in a double- blind
fashion and entered a 36-week titration and maintenance phase with regularly scheduled visits. Both efficacy parameters and
safety assessments were monitored. Clinical laboratory, evoked potential studies, MRI, and neuropsychological tests were also
performed.
Forty-eight percent of VGB-treated patients vs. 26 percent of placebo-treated patients had a 50 percent or greater reduction
in the frequency of complex partial seizures and partial seizures secondarily generalized. Vigabatrin was well tolerated by the
majority of patients. Minor neurological side effects were observed in a number of patients in both treatment groups. No serious
systemic toxicity was observed. No changes in evoked potential studies or MRI findings were noted.
Vigabatrin was found to be an effective and well-tolerated antiepileptic drug when used as adjunctive therapy in patients with
difficult to control complex partial seizures and for partial seizures secondarily generalized.
Vigabatrin is a selective irreversible inhibitor of the GABA- degradating enzyme GABA transaminase1–5 and has shown
efficacy in a number of clinical trials in patients with difficult to control partial seizures. Vigabatrin has been found most
effective against complex partial and secondarily generalized tonic–clonic seizures in both adults and children6–18. Vigabatrin
has also been shown to reduce infantile spasms secondary to various aetiologies and is most effective in spasms associated with
tuberous sclerosis19.
The aim of this study was to further extend the clinical experience with VGB as adjunctive therapy in the treatment of adult
patients with difficult to control complex partial seizures and/or partial seizures secondarily generalized. In addition to the
assessments of efficacy and tolerability to VGB, neuropsychological evaluations were also carried out.
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PATIENT POPULATION AND METHODS
Patient population
Patient recruitment was conducted in 10 centres lo-
cated in different cities across Canada, between De-
cember 1991 and December 1992. Ethics Review
Committee approval was obtained from each institu-
tion and each patient provided written informed con-
sent prior to the initiation of the study.
Patient of both genders, between 16 and 50 years
old at the time of entry, with a definite diagnosis
of complex partial seizures or partial seizures with
secondary generalization, (according to the 1981 re-
vision of the International Classification of Epilep-
tic Seizures) were entered. This diagnosis was con-
∗Editor’s note: the attention of UK readers is drawn to recent suggested restriction on the use of vigabatrin related to the potential side effect of
peripheral visual loss.
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firmed by documented focal EEG abnormalities. Pa-
tients were required to have a minimum of six complex
partial seizures or partial seizures secondarily general-
ized over the eight-week period preceding entry. These
patients were eligible if they had been, and still were,
on a stable regimen of one or two antiepileptic medi-
cations (AEDs) for at least 8 weeks, including the pre-
vious or current use of carbamazepine and/or pheny-
toin. Patients in whom a change in concomitant AEDs
was medically indicated during the baseline evaluation
phase could be enrolled if they were then on a stable
regimen for at least 8 weeks. Patients also had to dis-
play a minimum performance, verbal, and overall I.Q.
of 65. Women at risk of pregnancy were required to
have an intrauterine device in place or be taking an ef-
fective oral contraceptive agent for 6 months prior to
treatment allocation.
Patients with treatable causes of seizures, history of
status epilepticus occurring more than once during the
preceding six-month period, progressive neurological
disorders, or epilepsy surgery or surgery for a brain
tumour within the previous 6 and 12 months, respec-
tively, were not enrolled. Patients with a history of ra-
diation therapy to the brain, alcoholism, drug addic-
tion, major depression or other serious psychiatric dis-
orders were not enrolled, nor were patients with sig-
nificant systematic disease, patients who had used an
investigational drug within 60 days preceding entry
into the study, patients having discontinued any AED
within 60 days preceding the beginning of the study,
and patients displaying a seizure-free interval of more
than 28 days.
Study design
Eligible patients for the study entered an open baseline
period of 12 weeks, during which seizure frequency
and blood levels of concomitant AEDs were moni-
tored. Patients were then randomized to receive either
active medication or a matching placebo and entered
a 32-week titration phase at a starting dose of 500 mg
b.i.d. At eight-week intervals thereafter the daily dose
was increased by 1 gram (500 mg b.i.d.) up to a maxi-
mum of 4 grams. Patients not having experienced any
seizures during the last 6 weeks of any of these eight-
week intervals had their dose increased by one gram
and if complete seizure control was maintained, that
dose was continued throughout the remainder of the
segment. If, at the next visit additional seizures had oc-
curred, the patient continued dose escalation. Follow-
ing the titration phase, patients entered a maintenance
phase during which the dose reached after 32 weeks
of treatment was maintained for a further four-week
period for a total treatment duration of 36 weeks.
CLINICAL EVALUATION
Efficacy assessments
The assessment of efficacy was based on the daily
recording of seizures using diaries. Both the occur-
rence and the type of seizures were recorded.
Safety assessments
In addition to adverse event recording throughout the
study, the routine safety assessments included a phys-
ical and a neurological evaluation performed at each
study visit. Study visits were scheduled every 2–4
weeks according to protocol with no scheduling win-
dow. Clinical laboratory tests (biochemistry, haema-
tology, urinalysis) were conducted at the time of en-
try into the study, at the end of the baseline phase
and at each study visit throughout the remainder of
the study. Visual- and somatosensory-evoked poten-
tial measurements were carried out at the end of the
baseline and end of study. Brain magnetic resonance
imaging (MRI) evaluations were also conducted at the
end of the baseline and end of study. Both T2 axial
and coronal areas were covered at 5 mm intervals with
1.5 tesla equipment.
A battery of neuropsychological tests was also ad-
ministered to the patients at the end of the baseline
and end of study. Tests of adjustment included a vi-
sual analogue mood rating scale, the Profile of Mood
State Test (POMS), and the Washington Psychologi-
cal Seizure Inventory (WPSI). Tests aimed at assess-
ing abilities included the Lafayette Grooved Pegboard
Test, the Stroop Test, the Benton Visual Retention
Test, the Controlled Oral Association Test, a symbol
digit modalities test, the Rey Auditory Verbal Learn-
ing Test, the Wonderlic Personal Test, and a digit can-
cellation test. All these tests were performed according
to standardized procedures of administration.
Surveillance measures
Blood levels of concomitant AEDs were measured at
each study visit by a central laboratory using stan-
dardized analytical methods. Plasma levels of vigaba-
trin (VGB) were measured at end of baseline and at
each study visit thereafter by a central laboratory us-
ing a standardized high-pressure liquid chromatogra-
phy (HPLC) method.
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Table 1: Baseline characteristics of patients randomized to placebo and VGB treatment.
Variable Placebo VGB All patients Pa
(n = 53) (n = 58) (n = 111)
Gender
Males %(n) 55% (29) 55% (32) 55% (61) 1.00
Females %(n) 45% (24) 45% (26) 45% (50)
Age (years)
Median 34 34 34
Mean ± S.E.M. 34± 1.1 34± 1.0 34± 0.8 0.770
Range (18–49) (18–50) (18–50)
Number of concurrent AEDs
One %(n) 31% (16)b 29% (17) 30% (33)b 1.00
Two %(n) 69% (36) 71% (41) 70% (77)
Age at onset of epilepsy (years)
Median 12 11c 12c
Mean ± S.E.M. 14± 1.5 13± 1.2 13± 0.9 0.440
Range (1–44) (1–45) (1–45)
Duration of epilepsy (years)
Median 18 22c 20c
Mean ± S.E.M. 19± 1.4 21± 1.2 20± 0.9 0.154
Range (3–43) (4–41) (3–43)
a P values for categorical variables from Fisher’s exact test, for continuous variables from Wilcoxon Test.
b One patient did not use any concurrent antiepilepsy medication.
c One patient had a missing value.
Study medication compliance assessment
The study medication was supplied in double-blind
condition as 500 mg tablets of active medication or
matching placebo. Compliance was assessed using
overall drug accountability (pill counting) at each
visit.
Data analysis
Two patient subsets were prospectively defined for ef-
ficacy and safety analyses. The intention-to-treat pop-
ulation consisted of all randomized patients who con-
sumed double-blind study medication. Patients in this
dataset had disposition classifications of either pro-
tocol correct or not protocol correct. The intention-
to-treat dataset was used for all primary efficacy and
safety analyses. Supportive analyses were performed
using the protocol correct population which included
all randomized patients who completed all visits with
no major protocol violations.
The mean monthly seizure frequency was calculated
for each patient using the data recorded by the patients
in the daily seizure diaries. Information on simple par-
tial seizures (IA), complex partial seizures (IB), partial
seizures secondarily generalized (IC), and complex
partial seizures and partial seizures secondarily gen-
eralized (IB + IC) was obtained. The mean monthly
seizure-free days were calculated using the same ap-
proach.
Baseline characteristics were compared between the
two treatment groups using non-parametric statistics,
applying Fisher’s exact test or the likelihood ratio chi-
squared test for categorical variables and the Wilcoxon
Test for continuous variables. The primary assessment
of efficacy was based on the change from baseline in
the mean monthly seizure frequency observed in the
individual patients, using an analysis of covariance
model adjusting for baseline and investigative site. A
rank transformation was applied to the seizure fre-
quency prior to statistical analysis. The consistency
of the treatment effect was assessed across subgroups
of patients according to age, gender, weight and con-
current AEDs. Comparison between the two treatment
groups with regards to the number of patients reach-
ing therapeutic success, defined as a decrease of 50%
or more in the mean monthly frequency of complex
partial seizures and partial seizures secondarily gen-
eralized, was performed using a Cochran–Mantel–
Haenszel procedure, stratifying by investigative site.
This approach was also applied to the comparisons
pertaining to the global evaluation of therapeutic ef-
fect, the physician’s evaluation of tolerability, and the
physician’s global evaluation.
Changes from baseline in the evoked potential la-
tencies as well as in the neuropsychological test bat-
tery were compared between the two treatment groups
using the Wilcoxon Test. An analysis of correlation
was applied to the assessment of the relationship be-
tween plasma levels of VGB and percentage reduction
in seizure frequency (complex partial seizures and par-
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tial seizures secondarily generalized). The Wilcoxon
Test was used to compare the percentage reduction
from baseline in the plasma levels of concurrent AEDs




A total of 111 patients were randomized in the study;
53 in the placebo group, 58 on VGB. All results
presented are from the intention-to-treat analysis. As
shown in Table 1, the two treatment groups were sim-
ilar with regards to their baseline characteristics. The
patient population, with a slightly higher proportion of
males than females, was between 18 and 50 years of
age. The age of the patients at onset of epilepsy varied
between 1 and 45 years, and the duration of epilepsy at
the time of entry ranged between 3 and 43 years. Sev-
enty percent of the patients were taking two concomi-
tant AEDs at the time of entry into the study. These in-
cluded carbamazepine, phenytoin, valproic acid, ben-
zodiazepines and barbiturates (primidone or phenobar-
bital), which were used by 78, 31, 28, 21 and 12% of
patients, respectively (data not shown).
Of the 111 patients initially enrolled, 10
(placebo = 4, VGB = 6) prematurely discontinued
the treatment due to the adverse events as described
below (tolerability assessments). A further 11 pa-
tients (placebo = 5, VGB = 6) were excluded from
the protocol correct analysis of the primary efficacy
parameter because of major protocol violation (insuf-
ficient number of seizures during the baseline period
= 5; seizure-free interval > 28 days = 3; increase in
dosage of concomitant AEDs = 1; missing data = 1;
voluntary withdrawal = 1).
Study medication compliance assessment
The mean overall study medication compliance var-
ied between 75 and 108% in the placebo group
(mean± S.E.M. = 98± 1%) and between 80 and
104% in the VGB group (98± 1%) (data not shown).
Out of the 53 patients randomized to placebo,
47 (89%) completed the study on a daily dose equiv-
alent to 4 grams while (1.9%) and 0 (0%) com-
pleted on 3 and 2 grams/day, respectively. Similarly,
45 (78%), 5 (9%) and 2 (3%) of the 58 patients who
received VGB had reached a daily dose of 4, 3, and
2 grams, respectively, by the end of the study.
Table 2: Comparison of complex partial seizure (IB) frequency
between treatment groups.
Seizure frequency (number/28 days)
Treatment n Baseline median End of study median
(95% CI) (95% CI)
Placebo 53 7.0 6.0
(5.5–10.5) (4.5–8.7)
VGB 56b 6.5 3.0
(5.5–11.0) (1.5–4.0)
VGB vs. Placebo P = 0.0004a
a P value from analysis of covariance of the ranked end of study
seizure frequency using a model which adjusted for treatment,
investigative site, and ranked baseline seizure frequency.
b Two patients did not have complex partial seizures.
Table 3: Comparison of complex partial seizures plus partial
seizures secondarily generalized (IB+ IC) frequency between
treatment groups.
Seizure frequency (number/28 days)
Treatment n Baseline median End of study median
(95% CI) (95% CI)
Placebo 53 8.6 6.0
(6.0–10.5) (5.0–11.5)
VGB 58 7.3 3.5
(6.0–11.0) (2.5–4.5)
VGB vs. Placebo P = 0.001a
a P value from analysis of covariance of the ranked end of study
seizure frequency using a model which adjusted for treatment,
investigative site, and ranked baseline seizure frequency.
Efficacy assessments
Seizure frequency. Table 2 shows the median
monthly seizure frequency reported in both treatment
groups at baseline and at end of study. In the VGB
group, the frequency of complex partial seizures de-
creased from 6.5 (range = 5.5–11.0) to 3.0 (range =
1.5–4.0) seizures/28 days as compared with a decrease
from 7.0 (5.5–10.5) to 6.0 (4.5–8.7) in the placebo
group. The statistical comparison between the two
groups was highly significant in favour of the active
treatment group (P = 0.0004). Similar results were
obtained when comparing the frequency of complex
partial seizures plus partial seizures secondarily gen-
eralized which decreased from a median of 7.3 (6.0–
11.0) to 3.5 (2.5–4.5) seizures/28 days in patients who
received VGB while it decreased from 8.6 (6.0–10.5)
to 6.0 (5.0–11.5) in those on placebo (P = 0.001)
(Table 3).
The relationship between the daily dose of medi-
cation and the reduction observed in the two treat-
ment groups and the frequency of complex partial
seizures and partial seizures secondarily generalized
is depicted in Fig. 1. While this reduction varied be-
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Table 4: Comparison of seizure-free days between treatment
groups.
Seizure free days (number/28 days)
Treatment n Baseline median End of study median
(95% CI) (95% CI)
Placebo 53 21.0 22.0
(19.5–23.0) (20.0–24.0)
VGB 58 21.3 24.0
(17.5–22.5) (22.0–25.0)
VGB vs. Placebo P = 0.004a
a P value from analysis of covariance of the ranked end of study
seizure-free days using a model which adjusted for treatment,
investigative site, and ranked baseline seizure-free days.
tween 1.1 and 2.2 seizures/28 days in the placebo
group, a dose relationship emerged in patients on ac-
tive treatment in whom the reduction reached 2.5,
3.3, 3.7 and 4.0 seizures/28 days on 1, 2, 3 and
4 grams/day, respectively. The difference between the
two treatment groups reached statistical significance at
all dose levels (P = 0.02–0.05).
No statistically significant differences were ob-
served between the two treatment groups with re-
gards to the reduction in frequency of simple partial
seizures only (P = 0.389). This type of seizure was
reported in a small number of patients (placebo = 21,
VGB = 28) at low frequency. In the placebo group it
increased from 1.5 seizures/28 days (range = 0–12)
to 3.0 seizures/28 days (range = 0–11.3), while it de-
creased from 3.0 (1.0–6.5) to 1.3 (0.0–6.5) in the ac-
tive treatment group (data not shown).
A statistically significant difference (P = 0.004)
was observed between placebo and VGB with regards
to the change in the number of seizure-free days dur-
ing the study. (Table 4). This variable increased from
a median of 21 (range 19.5–23.0) to 22 (20.0–24.0) in
the placebo group as compared with an increase from
21 (17.5–22.5) to 24 (22.0–25.0) in patients receiving
VGB.
In addition, for all patients who received study med-
ication (VGB and placebo), no statistically signifi-
cant interactions were found between the change in
the frequency of complex partial seizures and par-
tial secondarily generalized and the patients’ gender
(P = 0.768) or the use of any of the concurrent AEDs
(P = 0.406–0.741), while a trend was observed with
regards to the patient body weight (P = 0.052) (data
not shown). A statistically significant difference was
found in the case of the patients’ age at onset of
epilepsy (P = 0.018). No clear pattern emerged, how-
ever, in the further evaluation of the latter interaction.
Therapeutic success. In the intention-to-treat anal-
ysis, the percentage of patients in whom a decrease
of 50% or more was observed by the end of the study
in the frequency of complex partial seizures and partial
Table 5: Comparison of therapeutic success between treat-
ment groups.
Therapeutic success:
≥50% reduction in mean monthly seizure rate
from baseline to end of study
Treatment n %(n)
Placebo 53 26% (14)
VGB 58 48% (28)
VGB vs. Placebo P = 0.022a
a P value from the comparison of the therapeutic success rate for
placebo and VGB, using the Cochran–Mantel–Haenszel Test
stratified by investigative site.
seizures secondarily generalized reached 48% (n =
28/58) in the VGB group and 26% (n = 14/53) in
the placebo group (Table 5). This difference reached
statistical significance (P = 0.022). A protocol cor-
rect analysis was also performed and the results sup-
port the conclusions of the intention-to-treat analysis.
Physician’s evaluation of therapeutic effect and global
evaluation. The assessment of the therapeutic effect
of the treatment was conducted by the investigators
at the end of the study period. From this evaluation,
two patients (4%) who had received the placebo were
recorded as seizure free as compared with 5 (9%) in
the group on VGB. Besides these patients, there were
38%, 55% and 8% of the patients on placebo who were
reported as improved, unchanged/minimally changed,
and worse, respectively, as compared with 67%, 24%
and 9% in the VGB group. These differences between
the two treatment groups reached a high statistical sig-
nificance level (P = 0.004). Similar results were also
obtained in a global evaluation of the treatment car-
ried out by the physicians taking into account their
overall impression about the treatment. In this eval-
uation, 36% of the patients on placebo were reported
as improved as compared with 54% in the VGB treat-
ment group, while approximately 10% in both treat-
ment groups were considered as having deteriorated
during the study (P = 0.047) (data not shown).
Tolerability assessments
Discontinuations related to adverse events. Ten pa-
tients were prematurely discontinued due to adverse
events; four patients from the placebo group (8%)
and six receiving VGB (10%). As shown in Table 6,
various events led to such discontinuation in both
treatment groups including central nervous system
and psychiatric-related events. Two of the patients on
VGB, one in whom schizophrenia was diagnosed and
the other who displayed an episode of psychotic de-
pression and convulsions, discontinued the treatment
due to events that were considered as being not related
to the study medication.
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Fig. 1: Reduction in seizure frequency of complex partial seizures plus partial secondarily generalized seizures (IB + IC) across
different daily doses of VGB.
Table 6: Discontinuations associated with adverse events.
Placebo (n = 4/53)
1. Insomnia, acne
2. Agitation, anxiety, amnesia, insomnia, hypoesthesia, headache,
tremor, fatigue, chest paina
3. Hot flushes
4. Drowsiness, hypokinesiaa, hypothyroidisma
VGB (n = 6/58)
1. Agitation, insomnia, headache, speech disorder, vertigo, nausea
2. Schizophreniaa
3. Drowsiness
4. Emotional lability, vision abnormal, headache, priapism, eye pain,
dyspepsia, constipation, gingivitis
5. Delirium, depression
6. Depression psychotica, convulsionsa
a Not related to study medication.
Premature discontinuations related to behavioural
adverse events occurred in one instance in the placebo
group and four patients in the VGB group. In the lat-
ter group these were observed following 3 to 5 months
of treatment at doses of either 2 or 3 grams per day.
Among these patients seizure reduction was null in
one case, moderate in two instances and marked in
one, indicating no clear relationship with the therapeu-
tic efficacy.
Adverse events. The most frequent treatment-related
adverse events reported during the study or adverse
events displaying a trend for a difference between the
two treatment groups are summarized in Table 7. Be-
sides an increase in body weight, which occurred with
a higher incidence in patients receiving the active med-
Table 7: Most frequent treatment-related adverse events.
System Placebo VGB
(n = 53) (n = 58)
Central nervous system
Headache 12 (23%) 19 (33%)
Fatique 9 (17%) 15 (26%)
Dizziness 7 (13%) 13 (22%)
Drowsiness 8 (15%) 10 (17%)
Insomnia 5 (9%) 6 (10%)
Vision abnormal 2 (4%) 8 (14%)
Diplopia 2 (4%) 6 (10%)
Amnesia 4 (8%) 9 (16%)
Confusion 2 (4%) 5 (9%)
Ataxia 0 (0%) 4 (7%)
Vertigo 0 (0%) 4 (7%)
Speech disorder 1 (2%) 5 (9%)
Psychiatric
Agitation 4 (8%) 7 (12%)
Aggressive reaction 0 (0%) 5 (9%)
Gastro-intestinal system
Dyspepsia 6 (11%) 5 (9%)
Metabolic & nutritional
Weight increase 1 (2%) 7 (12%)
ication, events with the highest incidence were related
to the central nervous system. While drowsiness, in-
somnia, agitation and dyspepsia were reported by a
similar number of patients in both treatment groups,
the incidence of adverse events tended in general to be
higher in patients on VGB.
A statistically significant difference in the change in
the body weight of the patients was found between the
two treatment groups (P = 0.001). While the change
between baseline and end of study was on average
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Table 8: Comparison of end of study physician’s overall as-
sessment of tolerability between treatment groups.
Assessment Placebo VGB
(n = 53) (n = 58)
% (n) % (n)
Extremely well tolerated 36% (19) 36% (21)
Well tolerated 55% (29) 36% (21)
Fairly well tolerated 2% (1) 16% (9)
Poorly tolerated 4% (2) 9% (5)
Very poorly tolerated 4% (2) 4% (2)
VGB vs. Placebo P = 0.076a
a P value from Cochran–Mantel–Haenszel procedure stratified by
investigative site.
Table 9: Comparison of fairly well tolerated or better in end of
study physician’s assessment of tolerability.
Treatment Fairly well tolerated or better % (n)
Placebo 93% (49/53)
VGB 88% (51/58)
0.5± 0.4 kg (mean± S.E.M.), it reached 2.0± 0.7 kg
in the active treatment group. However, a similar range
was observed in both treatment groups (placebo = −8
to + 12 kg; VGB = −18 to + 13 kg) indicating a
marked individual variability.
Physician’s overall assessment of tolerability. Ta-
bles 8 and 9 summarize the results of the overall as-
sessment performed by the investigator at the end of
the study on the tolerability of the patients to the study
mediation. According to this evaluation, 93% and 88%
of the patients were considered as tolerating the study
medication well in the placebo and VGB groups, re-
spectively. This difference was not statistically signif-
icant although a trend was observed (P = 0.076).
Safety assessments
No changes were observed in the respiration rate,
pulse or blood pressure (systolic and diastolic) in the
course of the study. There were no differences between
the two treatment groups (data not shown).
Although one patient receiving VGB had an increase
in the GGTP level, no clinically significant abnormali-
ties were observed at the end of the study with regards
to the clinical laboratory evaluations.
No changes were observed at the end of the study
in the evoked potential evaluations. Both treatment
groups had similar visual (P = 0.227–0.339) and so-
matosensory latencies (P = 0.400–0.916) (data not
shown).
Both the baseline and study termination MRI evalu-
ations were available in 31 (58%) and 36 (62%) of the
patients having received placebo or VGB, respectively.
Among these patients a difference between the base-
line and final evaluations was observed for one patient
in the placebo group who suffered a cerebral haem-
orrhage and subdural hematoma secondary to a skull
fracture.
Neuropsychological test battery. Statistically signif-
icant differences in change from baseline between
VGB and placebo at the nominal 0.05 level were
found in the POMS, WPSI, Stroop Test and mood rat-
ing scale. The VGB group had a statistically signifi-
cantly higher average change from baseline than the
placebo group for the confusion/bewilderment and to-
tal mood disturbance scores of the POMS, for the rare
items score of the WPSI and for the part I/number
errors score of the Stroop Test. The VGB group had
a significantly lower average change from baseline
than the placebo group for the vigour/activity score
of the POMS and for the rested/bushed, tense/relaxed,
happy/sad, stable/over emotional and total score (av-
erage) scores of the mood rating scale. Despite these
differences, a clear pattern could not be identified with
regards to the direction or magnitude of the changes
observed in the two treatment groups (between base-
line and end of study). In some cases, a deterioration
was observed in the VGB group, while in others, a
combination between an improvement in the placebo
group and a deterioration in the VGB group, accounted
for such differences.
Surveillance measures
Vigabatrin plasma levels. Data on plasma concentra-
tion of VGB at the end of the study were available
in 58 patients from the active treatment group. Re-
sults from this study have shown no correlation be-
tween the individual plasma levels and the reduction
in the frequency of complex partial seizures and par-
tial seizures secondarily generalized (correlation co-
efficient = −0.143) (data not shown). These results
support previous findings.
Concomitant AED plasma levels. No statistically sig-
nificant differences were observed at the end of the
study between the two treatment groups with regard
to the change in the individual plasma levels of carba-
mazepine (P = 0.122), primidone (P = 0.784), val-
proate (P = 0.212), or clobazam (P = 0.259). On the
other hand, a trend was observed with phenobarbital
P = 0.054) which increased 8% in the placebo group
but decreased by 10% in the VGB group. A highly sta-
tistically significant difference (P = 0.001) was ob-
served with regard to phenytoin levels of which the
levels remained unchanged in patients receiving the
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placebo (−4%), but decreased by 24% in the active
treatment group (data not shown). However, no pat-
tern emerged with regard to the efficacy of the study
medication in patients showing a decrease in pheny-
toin levels and those not displaying such a change.
DISCUSSION AND CONCLUSION
This study was a double-blind placebo-controlled
study of VGB in the treatment of adult patients with
complex partial seizures, with or without secondary
generalization. A statistically significant difference
was observed between treatment group and placebo
in both complex partial and secondarily generalized
seizures. The number of seizure-free days was also
significantly improved in the VGB-treated patients.
Forty-eight percent of VGB patients vs. 26 percent
of placebo-treated patients had a decrease in seizure
frequency of 50 percent or more. Ten patients were
prematurely discontinued because of adverse events
(four placebo, six VGB). Premature discontinuation
related to behavioural adverse events occurred in
four patients on VGB and one patient on placebo. Vi-
gabatrin was extremely well tolerated or well tolerated
by 72.4 percent of patients. The most common ad-
verse effects consisted of headache, fatigue, dizziness
and drowsiness. Only 12.1 percent of patients tolerated
VGB poorly or very poorly compared with 7.6 percent
of patients on placebo.
The results of this study confirm the findings of pre-
viously reported clinical trials6–18, 20. In most of these
studies, VGB was used as adjunctive therapy in pa-
tients with difficult to treat epilepsy. In addition, ap-
proximately 50 percent of patients experienced at least
a 50 percent reduction in seizure frequency.
No significant laboratory abnormalities were
recorded. In some non-primate animal models VGB
has been associated with intramyelinic oedema which
can be assessed by MRI and evoked potential tests. No
MRI or evoked potential abnormalities were recorded
to suggest intramyelinic oedema.
Vigabatrin is not a hepatic enzyme inducing or in-
hibiting drug and is not protein bound. Accordingly,
significant drug interactions would not be expected.
Phenytoin plasma levels decreased by 24 percent in
the VGB-treated group, but this interaction was not of
clinical significance. Changes in phenytoin doses were
not required.
In the neuropsychological test battery some differ-
ences in favour of placebo were seen in the POMS,
WPSI, Stroop Test and mood rating scale, but a clear
pattern could not be identified. Previous studies have
demonstrated no significant cognitive adverse effect of
VGB21, 22.
Although the clinical efficacy and safety of VGB
have largely been assessed with VGB used as adjunc-
tive therapy in refractory patients, a limited number of
comparative monotherapy trials have shown efficacy
and safety of VGB in newly diagnosed patients23, 24.
Due to the demonstration of a neuroprotective effect25
of VGB in animal models, further clinical studies will
help determine if VGB can prevent cognitive decline
in patients with epilepsy.
In conclusion, results from this study support previ-
ous findings that VGB is a highly effective and well-
tolerated antiepileptic drug in patients with difficult to
control seizures.
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